Several of the other studies we have supported include:
Investigating the Biology of Canine Met Mutations (Dr. Cheryl London, DVM, Ohio State University. Research has shown that mutations in a gene called Met contribute to the development of numerous types of cancer in humans and mice. This study is searching for genetic markers that will help better target cancer treatments and have identified 2 similar mutations in dogs, which have a high chance of developing cancer. The researchers are encouraged by their preliminary results with this inhibitor in several clinical cases of dogs diagnosed with osteosarcoma.
RNAi Delivery Vectors Target to Canine Tumors (Dr. D. Argyle, University of Edinburgh). This study ended in 2008. It identified a molecular target in cancer that is a near universal marker of malignancy. The study utilized RNA interference technology to develop a therapeutic strategy for cancers. They showed that the direct injection of these molecules may have an effect, albeit, not sustainable, in the cessation of cancer.